Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
RaySearch Laboratories AB (RSLBF) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of RaySearch Laboratories AB $18.15, price $16.50, upside +10.0%, quality 70 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? Yes
- Good quality? Yes
- Add to watchlist
RL
Some data
Sep 24, 2026
Some data
Sep 24, 2026
RaySearch Laboratories AB
RSLBF · USNeutralQuality growthThe stock looks roughly fairly valued with average quality.
·Fair value $18.15 · Fairly valued (+10.0%)
✓Quality 70/100
✓Healthy Growth (revenue 5y +15.6 %/yr)
✓Solidly profitable · 17.2% net margin (TTM)
✓Low debt · generates free cash flow
✓Wide moat 74/100
!Evidence only medium, so the estimate is less certain
Watch RaySearch Laboratories AB for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.
Watch for free
Pro now: $1 first month
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range $3.95 – $37.36 · fair‑value band $10.57 – $22.68 · the $16.50 price screens below the $18.15 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Company profile
RaySearch Laboratories AB (publ), a medical technology company, provides software solutions for cancer treatment worldwide.
Show more
RaySearch Laboratories AB (publ), a medical technology company, provides software solutions for cancer treatment worldwide. It offers RayStation, a treatment planning system for cancer centers; RayCare, an oncology information system for clinics; RayIntelligence, cloud-based oncology analytics system that cancer centers can use to gather, structure and analyze data; and RayCommand, a treatment control system designed to link the treatment machine and the treatment planning and oncology information systems. It also provides µ-RayStation* (Micro-RayStation), a software platform for planning and evaluation in small animal irradiation research; RayPlan, a treatment planning system; DrugLog, which verifies the identity and concentration of compounded injectables before administered to a patient; RayMigrate, allows users to convert Pinnacle patient data to RayStation format and/or to DICOM format; Machine Learning; and Liver Ablation Solutions. The company was founded in 2000 and is headquartered in Stockholm, Sweden.
Stock analysis
RaySearch Laboratories AB (RSLBF) currently trades at $16.50, while our model-based Fair Value estimate is $18.15, implying the stock looks roughly 9.1% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $18.56 per share, and 10 of the 26 models we run sit above the $16.50 price.
Bear case: the Asset-Based group reads lowest at $2.13, and 16 of the 26 models stay below the price. Evidence for this calculation is medium.
Scenario range: $10.57 (bear) to $22.68 (bull), the price of $16.50 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 70/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
RaySearch Laboratories AB reported revenue of 1.3B SEK in FY2025 versus 642M SEK in FY2021, a compound +20.3%/yr. Reported net income was 228M SEK in FY2025.
Key figures
Market cap $731M · P/E ratio 30.5 · P/S ratio 5.16 · EPS (TTM) $0.7000 · Dividend yield 14.1% · Net margin 16.9% · Return on equity 22.8% · Return on assets (EBIT) 6.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 54 out of 100 (medium confidence).
What moves the price
For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at 10%, RSLBF screens cheaper than that median.
Fair Value models
Bear $10.57
Fair Value $18.15
Bull $22.68
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.5293 per share) are deliberately not added.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF
$7.41
$11.65
$21.63
77
Growth DCF
$7.17
$12.34
$19.67
77
EPV
$7.05
$7.87
$8.55
74
All 26 models by family
DCF Models
FCF DCF
$7.41
$11.65
$21.63
77
Owner Earnings
$12.50
$23.05
$41.38
73
5Y Revenue Exit
$8.92
$16.63
$27.84
70
5Y EBITDA Exit
$15.47
$31.40
$53.13
72
5Y P/E Exit
$10.74
$20.73
$33.14
69
10Y Revenue Exit
$8.00
$14.93
$26.36
64
10Y EBITDA Exit
$12.40
$25.37
$48.18
64
10Y P/E Exit
$9.42
$17.83
$31.46
61
Earnings-Based
Graham-Dodd
$5.01
$30.82
$43.01
63
Lynch FV
$8.84
$12.63
$16.42
61
PEG = 1.0
$8.84
$12.63
$16.42
57
EPV
$7.05
$7.87
$8.55
74
Dividend Discount
Gordon GGM
$2.58
$4.65
$6.41
68
DDM Multi-Stage
$2.58
$4.25
$4.97
67
Multiples
P/E Multiple
$12.15
$16.20
$20.25
63
P/S Multiple
$9.39
$12.52
$15.65
58
P/B Multiple
$9.39
$12.52
$15.65
55
EV/EBIT
$13.09
$17.11
$21.12
66
EV/EBITDA
$20.85
$27.45
$34.05
67
EV/Revenue
$9.64
$13.32
$17.01
54
Asset-Based
NCAV (Graham)
$1.59
$2.13
$3.19
54
Growth DCF
Growth DCF
$7.17
$12.34
$19.67
77
Rev-Margin DCF
$8.92
$16.25
$26.66
70
Economic Profit
Residual Income
$4.09
$5.32
$8.78
74
ROIC Compounder
$7.97
$10.05
$12.59
72
Growth Earnings
Growth-Adj P/E
$12.99
$18.56
$24.12
67
Notify me when RSLBF reaches fair value
Put RSLBF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
70/100
Of which business quality 68 · Market factors (momentum, volatility) 41
Profitability
74
Margins and returns on capital today
Quality Growth
58
Are margins and returns improving?
Cashflow
61
Earnings quality: real cash, not paper profit
Fin. Strength
82
Balance sheet, leverage, solvency risk
Investment
45
Disciplined investing over empire-building
Low Volatility
33
Calm price path (market factor)
Momentum
38
Price trend over the last 3–12 months (market factor)
52W Momentum
55
Distance to the 52-week high (market factor)
Net Issuance
81
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+12.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.6%
Start year 2020 (pandemic). Over 10 years: +13.0% a year
Revenue growth 22 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.5%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
≈ +49.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+35.2%
Dividend (yield on the price)14.1%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.35.2% vs 12.5%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−1% → 22%
Start year 2020 (pandemic)
⚠ Approximate: the rate leans on 2025, which sits 179% above its own trend.
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+23.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (figures in SEK, Sweden: IMF forecast 2.0% a year to 2030, 2.9% from 2016 to 2025) that is about +20.7% a year for the price.
Watch RSLBF, get fair value alerts →
Compare RaySearch Laboratories AB with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 128 stocks
Beats the industry median on 7/11 measures
Overall it ranks above its industry peers.
Valuation Multiplesvs Health Information Services median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Health Information Services stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $278.57 | $306.43 | +10% |
| Pro Medicus Limited PME | A$161.00 | A$84.62 | −47% |
| BrightSpring Health Services, Inc BTSG | $56.54 | $25.86 | −54% |
| Hinge Health, Inc HNGE | $95.57 | $51.25 | −46% |
| HealthEquity, Inc HQY | $88.44 | $97.28 | +10% |
| Waystar Holding WAY | $24.70 | $27.17 | +10% |
| Doximity, Inc DOCS | $26.35 | $31.41 | +19% |
| XtalPi Holdings 2228 | HK$7.75 | HK$1.50 | −81% |
| Inventurus Knowledge Solutions Limited IKS | ₹1,779 | ₹1,883 | +6% |
| Privia Health Group PRVA | $19.62 | $5.02 | −74% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is RaySearch Laboratories AB (RSLBF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $18.15 versus a price of $16.50, about +10% upside (undervalued).
What is the fair value of RSLBF?
Our model-based fair value for RaySearch Laboratories AB is $18.15 (as of Sep 24, 2026), built from audited fundamentals. The current price: $16.50.
What is the quality score of RSLBF?
RaySearch Laboratories AB has a Quality Score of 70/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for RaySearch Laboratories AB (RSLBF)?
Our model-based price target is the fair value of $18.15 (as of Sep 24, 2026) from 26 valuation models. Cautious scenario $10.57, optimistic scenario $22.68. It is a calculation from audited fundamentals, not an analyst target.
What is the RaySearch Laboratories AB stock forecast for 2026?
Our models put fair value at $18.15, about +10% upside versus a price of $16.50 (undervalued). Cautious scenario $10.57, optimistic scenario $22.68. The calculation is refreshed regularly with new filings.
What is the revenue of RaySearch Laboratories AB (RSLBF)?
RaySearch Laboratories AB reported trailing-twelve-month revenue of about 1.3B SEK (latest available figure, as of Sep 24, 2026).
Does RaySearch Laboratories AB pay a dividend?
RaySearch Laboratories AB currently shows a dividend yield of about 14.06% relative to its recent price (as of Sep 24, 2026).
What growth is priced into RaySearch Laboratories AB (RSLBF)?
For today's price to be fair in a discounted-cash-flow model, RaySearch Laboratories AB would have to grow free cash flow by +23.1 % per year for five years (discount rate 11.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +15.6 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of RSLBF use?
Our models discount RaySearch Laboratories AB at 11.1 %: a base by market capitalisation (small), damped by beta 0.94, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For RaySearch Laboratories AB that is +23.1 % per year a year over ten years, using the same discount rate (11.1 %) and the same formula as our fair value.
How much growth has RaySearch Laboratories AB (RSLBF) delivered so far?
Over the past 5 years revenue at RaySearch Laboratories AB grew +15.6 % a year. The price currently implies +23.1 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of RaySearch Laboratories AB (RSLBF) growing?
The median revenue growth in the sector is +5.1 % a year. That is the yardstick for the growth priced into RaySearch Laboratories AB (+23.1 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of RaySearch Laboratories AB (RSLBF)?
The free-cash-flow yield on the price is 2.80 %: that much free cash flow RaySearch Laboratories AB produces per unit of market value. When it exceeds the discount rate of our models (11.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of RaySearch Laboratories AB (RSLBF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For RaySearch Laboratories AB it is $18.15 per share (as of Sep 24, 2026), against a price of $16.50. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is RaySearch Laboratories AB stock overvalued or undervalued in 2026?
As of Sep 24, 2026, RSLBF trades below its calculated fair value: price $16.50, fair value $18.15, a gap of about +10% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RSLBF?
No. The price is what the market pays today ($16.50); the fair value is what the company's own numbers justify ($18.15). For RaySearch Laboratories AB the two are $1.65 per share apart. That gap is exactly why we show both numbers side by side.
How much is RaySearch Laboratories AB worth?
The market values RaySearch Laboratories AB at about $731M (market capitalisation, as of Sep 24, 2026). Per share that is $16.50; our models calculate a fair value of $18.15 per share.
What do the bullish and bearish scenarios say about RSLBF?
Our models span a range for RaySearch Laboratories AB: cautious scenario $10.57, base $18.15, optimistic $22.68 per share (as of Sep 24, 2026, price $16.50). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of RSLBF?
RaySearch Laboratories AB trades at a price-to-earnings ratio of 30.5 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $18.15 is built from several models across several years.
How solid is the balance sheet of RaySearch Laboratories AB (RSLBF)?
Balance-sheet figures for RaySearch Laboratories AB (as of Sep 24, 2026): return on equity 22.8%, debt of 0.09 per unit of equity. They feed the Quality Score of 70/100, which measures business quality independently of the share price.
Which stocks are comparable to RaySearch Laboratories AB?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is RaySearch Laboratories AB stock attractive at the current price?
The data as of Sep 24, 2026: price $16.50, calculated fair value $18.15 (+10%), Quality Score 70/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of RSLBF calculated?
We run RaySearch Laboratories AB through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $18.15, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. RaySearch Laboratories AB currently trades 9 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of RaySearch Laboratories AB (RSLBF)?
The closing price on Oct 2, 2026 was $16.50. Our model-based fair value is $18.15, about +10% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with RaySearch Laboratories AB right now?
A fairly wide model range ($10.57 to $22.68) leaves room in how you read the outcome. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Where does the earnings growth of RaySearch Laboratories AB (RSLBF) come from?
Earnings per share at RaySearch Laboratories AB grew +6.9 % a year from 2014 to 2025. Broken into its drivers: revenue per share +12.7 %, EBIT margin −5.4 %, tax rate +0.2 %, residual (interest, one-offs) +0.0 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of RaySearch Laboratories AB
How large is the market capitalisation of RaySearch Laboratories AB (RSLBF)?
The market capitalisation of RaySearch Laboratories AB is $731M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of RaySearch Laboratories AB (RSLBF)?
The price-to-sales ratio of RaySearch Laboratories AB is 5.16 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of RaySearch Laboratories AB (RSLBF)?
Earnings per share at RaySearch Laboratories AB are $0.7000 (price ÷ EPS = P/E 30.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of RaySearch Laboratories AB (RSLBF)?
The dividend yield of RaySearch Laboratories AB is 14.1%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of RaySearch Laboratories AB (RSLBF)?
The net margin of RaySearch Laboratories AB is 16.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of RaySearch Laboratories AB (RSLBF)?
The return on equity (ROE) of RaySearch Laboratories AB is 22.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of RaySearch Laboratories AB (RSLBF)?
On an EBIT basis the return on assets of RaySearch Laboratories AB is 6.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How fast is revenue growing at RaySearch Laboratories AB (RSLBF)?
Revenue at RaySearch Laboratories AB is growing −12.3% versus a year earlier (3y avg +16.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at RaySearch Laboratories AB (RSLBF)?
Earnings per share at RaySearch Laboratories AB are growing −6.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does RaySearch Laboratories AB (RSLBF) hold?
RaySearch Laboratories AB holds more cash than debt, 12.5M SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch RaySearch Laboratories AB in the live analysis
One click puts RaySearch Laboratories AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.